Omzet 2024 * | 102 mln. 93,58 mln. | Omzet 2025 * | 114 mln. 105 mln. | Marktkapitalisatie | 235 mln. 217 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -13 mln. -11,98 mln. | Nettowinst (verlies) 2025 * | -12 mln. -11,05 mln. | EV/omzet 2024 * | 2,32 x |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | 2,07 x |
K/w-verhouding 2024 * |
-16,7
x | K/w-verhouding 2025 * |
-20,6
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 79,76% |
Recentste transcriptie over OptimizeRx Corporation
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Will Febbo
CEO | Chief Executive Officer | 55 | 22-02-16 |
Edward Stelmakh
DFI | Director of Finance/CFO | 58 | 11-10-21 |
President | 46 | 29-04-19 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Gregory Wasson
BRD | Director/Board Member | 65 | 21-07-20 |
Catherine Klema
BRD | Director/Board Member | 65 | 24/01 |
Patrick Spangler
BRD | Director/Board Member | 68 | 27-03-18 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+30,65% | 470 mld. | |
+33,63% | 276 mld. | |
+3,90% | 135 mld. | |
+30,50% | 94,76 mld. | |
+62,27% | 61,13 mld. | |
+14,09% | 46,6 mld. | |
+25,91% | 38,08 mld. | |
-0,62% | 35,74 mld. | |
+12,07% | 29,13 mld. |